Wednesday, June 10, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
84
Drugs
37
Patents
379
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Alnylam Netherlands projects

33 ClinicalTrials.gov programs sponsored by Alnylam Netherlands.

Alnylam Netherlands has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

33 programs

Clinical programs

  1. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  2. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  3. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

  4. ALN-6400

    Alnylam Netherlands B.V.

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  5. ALN-6400

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia

    phase 2 small molecule active

    1 trial

  6. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

  7. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  8. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  9. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  10. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  11. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  12. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  13. ALN-XDH

    Alnylam Netherlands B.V.

    Gout

    phase 2 small molecule terminated

    1 trial

  14. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 2 small molecule completed

    1 trial

  15. Indapamide

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  16. Lumasiran

    Alnylam Netherlands B.V.

    Recurrent Calcium Oxalate Kidney Stone Disease

    phase 2 small molecule terminated

    1 trial

  17. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 2 small molecule completed

    1 trial

  18. Lumasiran

    Alnylam Netherlands B.V.

    PH1

    phase 2 small molecule completed

    1 trial

  19. Lumasiran

    Alnylam Netherlands B.V.

    Haemodialysis

    phase 2 small molecule active

    1 trial

  20. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  21. Patisiran

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  22. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  23. Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy

    phase 2 small molecule active

    1 trial

  24. Placebo

    Alnylam Netherlands B.V.

    IgA Nephropathy (IgAN)

    phase 2 small molecule terminated

    1 trial

  25. Placebo

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  26. Revusiran

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  27. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  28. VIR-2218

    Alnylam Netherlands B.V.

    Chronic Hepatitis B

    phase 2 small molecule completed

    2 trials

  29. VIR-2218

    Alnylam Netherlands B.V.

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  30. Zilebesiran

    Alnylam Netherlands B.V.

    High Cardiovascular Risk

    phase 2 small molecule completed

    1 trial

  31. Zilebesiran

    Alnylam Netherlands B.V.

    Mild to Moderate Hypertension

    phase 2 small molecule completed

    1 trial

  32. cemdisiran

    Alnylam Netherlands B.V.

    Atypical Hemolytic Uremic Syndrome

    phase 2 small molecule terminated

    2 trials

  33. phosphate-buffered saline for SC administration

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia (HHT)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Alnylam Netherlands have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.